
To compare the efficacy of triple therapy (metformin/exenatide/pioglitazone) versus stepwise conventional therapy (metformin → glipizide → glargine insulin) on liver fat content and hepatic fibrosis in newly diagnosed, drug‐naïve patients with type 2 diabetes. Sixty‐eight patients completed the 6‐year follow‐up and had an end‐of‐study (EOS) FibroScan to provide measures of steatosis (controlled attenuation parameter [CAP] in dB/m) and fibrosis (liver stiffness measurement [LSM] in kPa); 59 had magnetic resonance imaging‐proton density fat fraction (MRI‐PDFF) to measure liver fat. At EOS, HbA1c was 6.8% and 6.0% in triple and conventional therapy groups, respectively (P = .0006). Twenty‐seven of 39 subjects (69%) receiving conventional therapy had grade 2/3 steatosis...
Like
Save
Share